Literature DB >> 15154399

Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics.

Ganesh Dakhale1, Suchet Khanzode, Shruti Khanzode, Anand Saoji, Linesh Khobragade, Avinash Turankar.   

Abstract

There is evidence to suggest the derangement of the oxidant and antioxidant defense system in schizophrenia. The present study examined the effect of atypical antipsychotics on lipid peroxidation, superoxide dismutase (SOD) and ascorbic acid. For this purpose, a prospective, open-label, 8-week study design was utilized. Serum SOD, serum malondialdehyde (MDA) and plasma ascorbic acid were estimated. Schizophrenic patients (n = 48) were compared with age- and sex-matched healthy volunteers (n = 40). There was a significant increase in serum SOD, serum MDA and a decrease in plasma ascorbic acid in schizophrenic patients as compared to control subjects. The trend altered significantly after the treatment with atypical antipsychotics. The results of the Brief Psychiatric Rating Scale for schizophrenia also improved with the treatment. The findings indicate an involvement of free radicals in schizophrenia and its modification by treatment with atypical antipsychotics. This study can also be used as a predictor of drug response by atypical antipsychotics in schizophrenia. Copyright 2004 Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15154399     DOI: 10.1159/000077368

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  32 in total

1.  Epicatechin inhibits human plasma lipid peroxidation caused by haloperidol in vitro.

Authors:  Anna Dietrich-Muszalska; Bogdan Kontek; Beata Olas; Jolanta Rabe-Jabłońska
Journal:  Neurochem Res       Date:  2011-11-12       Impact factor: 3.996

Review 2.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

Review 3.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

Review 4.  Viral infection, inflammation and schizophrenia.

Authors:  Rachel E Kneeland; S Hossein Fatemi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-02-10       Impact factor: 5.067

Review 5.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

6.  Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia.

Authors:  G N Dakhale; S D Khanzode; S S Khanzode; A Saoji
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

7.  Evaluation of oxidative stress measurements in obstructive sleep apnea syndrome.

Authors:  W Jordan; S Cohrs; D Degner; A Meier; A Rodenbeck; G Mayer; J Pilz; E Rüther; J Kornhuber; S Bleich
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

8.  The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): comparison.

Authors:  Anna Dietrich-Muszalska; Justyna Kopka; Anna Kwiatkowska
Journal:  Neurochem Res       Date:  2013-04-26       Impact factor: 3.996

9.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

10.  Evaluation of antioxidant deficit in schizophrenia.

Authors:  Gora Dadheech; Sandhya Mishra; Shiv Gautam; Praveen Sharma
Journal:  Indian J Psychiatry       Date:  2008-01       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.